Skip to main content

Key Product Details

Species Reactivity

Human

Applications

CyTOF-ready, Flow Cytometry

Label

FITC (Excitation = 495 nm, Emission = 519 nm)

Antibody Source

Recombinant Monoclonal Mouse IgG2B Clone # 545422

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

NS0 mouse myeloma cell line transfected with human TSPAN33
Met1-Tyr283
Accession # NP_848657

Specificity

Detects HEK293 human embryonic kidney cell line transfected with human TSPAN33 by Flow Cytometry. Does not detect untransfected or irrelevant transfected HEK293 cells.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2B

Applications for TSPAN33 Antibody (545422) [FITC]

Application
Recommended Usage

CyTOF-ready

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Formulation

PBS

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: TSPAN33

Long Name

Tetraspanin 33

Alternate Names

PEN, Penumbra

Gene Symbol

TSPAN33

Additional TSPAN33 Products

Product Documents for TSPAN33 Antibody (545422) [FITC]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for TSPAN33 Antibody (545422) [FITC]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...